OSE Immunotherapeutics SA (LON:0RAD)
5.43
-0.07 (-1.31%)
At close: Nov 6, 2025
OSE Immunotherapeutics Revenue
In the year 2024, OSE Immunotherapeutics had annual revenue of 83.44M EUR with 3,646.52% growth. OSE Immunotherapeutics had revenue of 862.00K in the half year ending December 31, 2024, a decrease of -61.77%.
Revenue
83.44M EUR
Revenue Growth
+3,646.52%
P/S Ratio
1.52
Revenue / Employee
1.30M EUR
Employees
64
Market Cap
105.10M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.44M | 81.21M | 3,646.52% |
| Dec 31, 2023 | 2.23M | -16.08M | -87.83% |
| Dec 31, 2022 | 18.30M | -8.00M | -30.43% |
| Dec 31, 2021 | 26.31M | 15.89M | 152.48% |
| Dec 31, 2020 | 10.42M | -15.53M | -59.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shell | 200.18B |
| BP p.l.c. | 138.32B |
| Unilever | 51.24B |
| AstraZeneca | 43.24B |
| HSBC Holdings | 43.13B |
| Rio Tinto Group | 39.22B |
| GSK plc | 32.17B |
| British American Tobacco p.l.c. | 25.60B |